# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Reneo Pharmaceuticals (NASDAQ:RPHM) reported quarterly losses of $(0.16) per share. This is a 75.38 percent increase over losse...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Reneo Pharmaceuticals (NASDAQ:RPHM) with a Neutral and maintains ...
Reneo and Onkure announced Monday that they have entered into a definitive merger agreement to combine the two companies in an ...